Last Posted: Feb 18, 2018
- Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients with Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia
DG Karalis et al, Am J Cardio, Feb 2018 - Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.
Baragetti Andrea et al. Pharmacological research 2018 Feb 1-11 - Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?
Ghaleb Youmna et al. European journal of human genetics : EJHG 2018 Jan - Multilocus Analysis of Genetic Susceptibility to Myocardial Infarction in Russians: Replication Study.
Kukava N G, et al. Acta naturae 0 0 (4) 74-83 - Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
JA Doshi et al, Circulation Cardiovascular Disease, Jan 2018 - Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
Luo Huaichao, et al. Journal of genetics 2017 12 (6) 985-992
.png)
No hay comentarios:
Publicar un comentario